Kalohexis Announces First Patients Dosed in First-in-Human Phase 1 Clinical Trial of 710GO for General Obesity
710GO is a next-generation, first-in-class oral dual MC3R/MC4R agonist designed to activate the melanocortin system to induce healthier, more durable weight loss NORTHBROOK, Ill., May 28, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the...
710GO is a next-generation, first-in-class oral dual MC3R/MC4R agonist designed to activate the melanocortin system to induce healthier, more durable weight loss NORTHBROOK, Ill., May 28, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.